Matthew T Reynolds, PA-C

Jayme Heim, MSN, FNP-BC, and Matthew T. Reynolds, PA-C, shares clinical pearls for clinicians managing patients with plaque psoriasis.

Matthew T. Reynolds, PA-C, comments on how evaluating treatment profiles, comorbidities, age, and population can help the clinician understand plaque psoriasis and improve management strategies.

Jayme Heim, MSN, FNP-BC, and Matthew T. Reynolds, PA-C, discuss implications of real-world data on the use of IL-23 inhibitors in treatment of plaque psoriasis for older patients.

Experts in psoriasis examine the implications of long-term data for IL-23 inhibitors, especially in patients who have not responded to initial treatment of plaque psoriasis.

Jayme Heim, MSN, FNP-BC, and Matthew T. Reynolds, PA-C, comment on potential safety concerns and adverse events regarding the use of IL-23 inhibitors as well as the long-term safety and efficacy of these therapies in plaque psoriasis.

Matthew T. Reynolds, PA-C, reviews the route of administration and dosing frequencies of current/approved IL-23 inhibitors tildrakizumab, guselkumab, and risankizumab for treatment of plaque psoriasis.

Matthew T. Reynolds, PA-C, reviews the mechanism of action of IL-23 inhibitors for the treatment of plaque psoriasis.

An expert nurse practitioner and a physician assistant examine the role of collaborative care in the management of plaque psoriasis.

Jayme Heim, MSN, FNP-BC, and Matthew T. Reynolds, PA-C, highlight the importance of the initial patient/provider conversation in guiding treatment of plaque psoriasis.

Matthew T. Reynolds, PA-C, shares his treatment approach to plaque psoriasis based on the expanding therapeutic landscape.

Jayme Heim, MSN, FNP-BC, and Matthew T. Reynolds, PA-C, provide an overview of the pathogenesis of plaque psoriasis and how our understanding of the condition has evolved.